Journal of Diabetes最新文献

{"title":"Diabetic Kidney Disease Update","authors":"Christian Mende, Zachary Bloomgarden","doi":"10.1111/1753-0407.70150","DOIUrl":"https://doi.org/10.1111/1753-0407.70150","url":null,"abstract":"<p>The major determinants of the development of chronic kidney disease (CKD) in people with diabetes are hyperglycemia, hypertension, genetic susceptibility, dyslipidemia, and inflammation. By better understanding these factors, we can modify the risk of kidney damage and subsequent complications among people with diabetes. Elevation in glucose levels leads to both metabolic and hemodynamic changes, including glomerular hyperfiltration, podocyte injury, and progressive albuminuria, while hypertension accelerates glomerular damage [<span>1</span>]. Genetic predisposition, along with lifestyle factors such as obesity and smoking, further increases the risk. Dyslipidemia and oxidative stress contribute to endothelial dysfunction and tubulointerstitial injury [<span>2</span>], and inflammation [<span>3</span>] and activation of fibrotic pathways play important roles in disease progression [<span>4, 5</span>].</p><p>CKD is defined operationally by estimated glomerular filtrate rate (eGFR) < 60 mL/min and urine albumin/creatinine ratio (UACR) ≥ 30 mg/g present for 90 days or longer. Diabetes is responsible for roughly one-quarter to one-half of all CKD cases, with the proportion varying by region, population demographics, and stage of kidney disease [<span>6-8</span>]. This underscores the critical importance of diabetes prevention and optimal management to reduce the global burden of CKD. Albuminuria with normal renal function and/or an eGFR < 60 mL/min is associated with considerable cardiovascular mortality and heart failure risk. This has been underappreciated compared to the risk of progression of CKD and ESKD. In diabetic CKD, the risk of cardiovascular death is twice as great with eGFR < 60 mL/min and four times as great with eGFR < 45 mL/min, compared to normal renal function [<span>9</span>]. Compared to no albuminuria, mortality and heart failure admissions are four- and five-fold more likely in the presence of albuminuria, even when the eGFR is normal [<span>10, 11</span>].</p><p>Pharmacologic therapy is the cornerstone of treatment of diabetic CKD, with improvement in outcome seen with Renin-Angiotensin-Aldosterone system (RAAS) blockade, including mineralocorticoid inhibitors (MRA), sodium glucose transporter (SGLT) 2 inhibitors, and glucagon-like peptide (GLP)-1 receptor agonists (RA); significant therapeutic benefits also have been shown with aggressive therapy of comorbidities (hypertension, obesity and dyslipidemia) [<span>12</span>]. However, lifestyle modifications (diet/weight management, physical activity, smoking) and genetic risk have not received as much attention in clinical practice [<span>13</span>]. In a Dutch observational study, only 2% of patients adhered to all recommended lifestyle recommendations [<span>14</span>].</p><p>Three publications in the current Journal of Diabetes evaluate the aspects of the effects of lifestyle, social factors, genetic risks, and comorbidities as risk factors for the progression ","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 9","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70150","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial","authors":"Shujing Wu,&nbsp;Huajie Xu,&nbsp;Lili Xu,&nbsp;Huanyi Zhang,&nbsp;Kang Cheng,&nbsp;Xiaoyan Wang,&nbsp;Manhua Chen,&nbsp;Guangping Li,&nbsp;Jiangnan Huang,&nbsp;Jun Lan,&nbsp;Guanghe Wei,&nbsp;Xin Zhao,&nbsp;Zhiyong Qi,&nbsp;Juying Qian,&nbsp;Hongyi Wu,&nbsp;Junbo Ge,&nbsp;the OPTION investigators","doi":"10.1111/1753-0407.70152","DOIUrl":"https://doi.org/10.1111/1753-0407.70152","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite increased risk of ischemic events in diabetes, the optimal anti-thrombotic strategy for secondary prevention has not been defined. We aimed to assess the efficacy and safety of optimal antiplatelet agents such as indobufen-based dual antiplatelet therapy (DAPT) in patients with diabetes after coronary stenting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>OPTION trial was a randomized, open-label, noninferiority, and multicentric study in China. Enrolled subjects were randomized 1:1 to indobufen-based DAPT or aspirin-based DAPT. This post hoc analysis from OPTION trial was performed by the presence of diabetes. The primary endpoint was a 1-year composite of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, definite or probable stent thrombosis, or Bleeding Academic Research Consortium (BARC) criteria type 2, 3, or 5 bleeding.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 4551 OPTION patients, the primary endpoint occurred in 93/1570 patients with diabetes (5.92%), as compared to 148/2981 without diabetes (4.96%) (HR: 0.72, 95% CI: 0.47–1.08, and HR: 0.73, 95% CI: 0.53–1.01, respectively), without significant interaction between diabetes status and treatment effect (<i>P</i>_interaction = 0.935). The secondary efficacy endpoint was comparable between patients with (HR: 1.31, 95% CI: 0.60–2.84) and without diabetes (HR: 0.95, 95% CI: 0.51–1.76) (<i>P</i>_interaction = 0.526). Similarly, both subgroups derived similar benefits for the safety endpoint (HR, 0.56; 95% CI, 0.34–0.92 for subjects with diabetes vs. HR, 0.66; 95% CI, 0.45–0.98 for those without diabetes; <i>P</i>_interaction = 0.609).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In patients receiving DES implantation, indobufen-based DAPT might be considered as a reasonable alternative to aspirin-based DAPT in the secondary prevention for those with diabetes, especially in patients at high bleeding risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 9","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70152","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Stressful Life Events With Diabetes Incidence in China: Insights From the China Kadoorie Biobank","authors":"Jing Qian,&nbsp;Huiying Cheng,&nbsp;Xuening Dai,&nbsp;Dianjianyi Sun,&nbsp;Pei Pei,&nbsp;Meng Wang,&nbsp;Yingjun Li","doi":"10.1111/1753-0407.70149","DOIUrl":"https://doi.org/10.1111/1753-0407.70149","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Limited empirical evidence exists on the link between exposure to various stressful life events (SLEs) and the heightened risk of Diabetes Mellitus (DM) within the mainland Chinese population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted this prospective cohort study with 455,464 participants from the China Kadoorie Biobank (CKB); we examined associations between SLEs exposures and DM outcomes. We employed multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for potential confounders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Over a median follow-up of 10.1 years, 14,218 DM cases were identified. A dose–response relationship was observed between the number of SLEs, personal-related events, and the risk of DM. The higher the number of SLEs experienced, the higher the risk of developing diabetes (HR = 1.06, 95% CI = 1.01–1.12); individuals who experienced personal-related events had a higher risk of developing DM (HR = 1.17, 95% CI = 1.01–1.36), and those who experienced marital separation/divorce had a 53% increased risk of DM (HR = 1.53, 95% CI = 1.12–2.09). Subgroup analyses revealed effect modifications based on birth cohort, sex, and area.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>By exploring the association of multiple SLEs with the development of DM, we identified marital separation/divorce as a driver of increased DM risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 9","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70149","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials","authors":"Jingqi Chen,&nbsp;Qiufeng Zhang,&nbsp;Qingping Wu,&nbsp;Xiaoming Zhang,&nbsp;Zhiyi Xiang,&nbsp;Sidong Zhu,&nbsp;Tianfu Dai,&nbsp;Yuexiu Si","doi":"10.1111/1753-0407.70151","DOIUrl":"https://doi.org/10.1111/1753-0407.70151","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive search of electronic databases, including PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov, was conducted from the inception of the databases. The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This meta-analysis included data from 25 randomized controlled trials (RCTs). The results indicated no significant difference in the incidence of suicidal behavior between the GLP-1 RA exposure group and the control group (RR = 0.84, 95% CI: 0.54–1.32, <i>p</i> = 0.46, <i>I</i>² = 0%). Subgroup analysis showed no significant differences in the incidence of suicidal behavior among participants with T2DM (RR = 0.74), obesity (RR = 1.07), adolescents (RR = 0.91), and adults (RR = 0.84). Additionally, no significant differences were observed between the two groups in any type of suicidal behavior, including suicidal ideation (RR = 1.04), suicide attempts (RR = 0.68), depression-related suicides (RR = 0.65), and completed suicides (RR = 1.06). There were also no significant differences between the groups for any type of GLP-1 RA, including dulaglutide (RR = 0.46), exenatide (RR = 0.98), semaglutide (RR = 0.82), lixisenatide (RR = 1.25), and liraglutide (RR = 0.92). No significant differences were observed between the exposure group and control group according to different comparators, including placebo (RR = 0.91) and others (RR = 1.08). All subgroup analyses showed <i>p</i>-values greater than 0.05 (two-sided tests) and <i>I</i>² values of 0%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings suggest that there is no significant association between GLP-1 RA exposure and suicidal behaviors in patients with T2DM or obesity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 9","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Commentary on “Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients With Type 2 Diabetes: A National Prospective Cohort Study”","authors":"Lei Xi,&nbsp;Juan Shi,&nbsp;Ying Peng,&nbsp;Yifei Zhang,&nbsp;Yanan Cao,&nbsp;Weiqing Wang","doi":"10.1111/1753-0407.70145","DOIUrl":"https://doi.org/10.1111/1753-0407.70145","url":null,"abstract":"<p>We thank the authors for their insightful comments and for recognizing that our manuscript provides valuable details about behavioral and genetic factors affecting the risk of obesity in people with type 2 diabetes (T2D) [<span>1</span>].</p><p>Firstly, as mentioned in our article, there may be recall bias based on patient self-reported sleep duration, and objectively measuring habitual sleep duration using actigraphy can provide more reliable data. However, considering its simplicity, practicality, and correlation with instrument measurement results, patients' self-reported sleep duration is still internationally recognized and widely used in population-based studies [<span>2, 3</span>].</p><p>Secondly, the relationship between sleep, diabetes and obesity is really complex and challenging. As mentioned by the authors, most exploratory experiments on sleep are temporary, especially for sleep deprivation. There are interactions among sleep, diabetes and obesity that impact cardiovascular and metabolic health, just like the intertwined trio. To avoid the potential impact of sleep related diseases, we excluded patients who reported implausible values of sleep duration (i.e., &lt; 3 or &gt; 12 h/night), use of sleeping aids, or psychiatric medications at baseline. It should be pointed out that the above efforts cannot completely eliminate the potential impact of sleep disorders on our study results, and how to reduce their potential effects is also one of the key considerations in our future research. The Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS) are indeed effective tools.</p><p>As we mentioned in the article, we acknowledge that “although we have adjusted for several covariates, there are potential confounders that could influence the results, such as dietary habits, physical activity, socioeconomic biases, and glucose-lowering medications, which we did not include in this study, and further research is needed to strengthen our understanding of these complex associations”, when it comes to both clinical and genetic analysis. In addition, a more complex and precise polygenic risk score (PRS) model for body mass index (BMI) is also under consideration.</p><p>In conclusion, we thank the authors for the wise and valuable comments and suggestions. We hope these clarifications address the issues raised and we intend to use more complex and appropriate models to explore their associations in future research.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70145","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144891692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Update on GLP-1 Receptor Agonists","authors":"Zachary Bloomgarden","doi":"10.1111/1753-0407.70147","DOIUrl":"https://doi.org/10.1111/1753-0407.70147","url":null,"abstract":"<p>The glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medications primarily developed for the management of type 2 diabetes (T2D) and are increasingly being used for various other health effects. Here's a simplified overview of their history, effects, and future prospects:</p><p>Glucose-dependent insulinotropic polypeptide (GIP) and then GLP-1 were identified in the 1970s as peptides potentiating the insulin secretory response to nutrient ingestion. In the early 1980s, the proglucagon amino acid sequence and gene were mapped, leading to the recognition of the common derivation of GLP-1 and GLP-2, produced in the L-cells of the distal small intestine, while GIP is produced in the K-cells of the proximal small intestine. The first therapeutically used GLP-1RA was isolated as exendin-4 from the saliva of a venomous lizard, <i>Heloderma suspectum</i> (the “Gila monster”), in 1992, with initial preclinical studies reported in 1996; although FDA approval for its use in treatment of T2D as exenatide was not granted until 2005. The next GLP-1RA used therapeutically was liraglutide, receiving approval in 2010, with dulaglutide receiving approval in 2014, semaglutide approval in 2017, and tirzepatide (a combined agonist of GLP-1 and GIP) approval in 2022; FDA approvals of liraglutide, semaglutide, and tirzepatide for treatment of obesity were granted in 2014, 2021, and 2023, respectively.</p><p>Both the GLP-1 and GIP receptor agonists enhance insulin production when glucose levels are elevated. This physiological insulin-secretory effect contrasts with the action of the older sulfonylureas, which activate the ATP-sensitive potassium channels of the pancreatic beta cells, mimicking the cellular process that physiologically acts to link insulin production to the beta cell's energy state. The consequent increase in endogenous insulin production leads the GLP-1RAs to have glucose-lowering action comparable to that of daily treatment with basal insulin [<span>1</span>]; with weight loss rather than weight gain and with lower likelihood of hypoglycemia [<span>2, 3</span>].</p><p>In addition to their glycemic benefits, GLP-1RAs are associated with improvement in mortality and in CV and renal outcomes in clinical trials [<span>4, 5</span>], both in people having and not having T2D [<span>6</span>], as well as in real-world studies of people with T2D [<span>7</span>] and of people with obesity without T2D [<span>8</span>]. In a study from the US Veteran's Affairs hospitals with mean followup of nearly 4 years comparing more than 200 000 persons receiving GLP-1RA with more than 1.2 million receiving usual care, benefits of GLP-1RAs included reduction in risk of stroke, myocardial infarction, pulmonary embolism, phlebitis, heart failure, hepatic failure, chronic kidney disease, bacterial infections, postprocedural respiratory complications, aspiration pneumonitis, chronic obstructive pulmonary disease, pneumonia and respiratory failure, a","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144888188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Serum Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A 3-Year Longitudinal Cohort Study (2019–2022)","authors":"Hui Zhao,&nbsp;Ze-wen Zhang,&nbsp;Tao Luo,&nbsp;Dilihumaer Aili,&nbsp;Wen-huan Ding,&nbsp;Yuan-yuan Li,&nbsp;Yuan-sheng Gu,&nbsp;Shulipan Aslibek,&nbsp;Jing-jing He,&nbsp;Wen-hui Yu,&nbsp;Run-ze Ma,&nbsp;Anaer Gaoshao,&nbsp;Ting-ting Qiao,&nbsp;Guo-zhen Zhang,&nbsp;Henry S. Lynn,&nbsp;Mu-long Du,&nbsp;Jiang-hong Dai","doi":"10.1111/1753-0407.70137","DOIUrl":"https://doi.org/10.1111/1753-0407.70137","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cardiovascular-kidney-metabolic (CKM) syndrome begins with obesity and glucose abnormalities, advancing to cardiovascular and kidney complications. This study investigates the relationship of advanced glycation end products (AGEs) with CKM syndrome staging and transition patterns.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This 3-year longitudinal study (2019–2022) of 1264 adults identified five CKM trajectory groups: Group 1 (stable low-risk, 6.7%, stage 0/1), Group 2 (fluctuating, 15.8%, stages 0/1–2), Group 3 (stable intermediate, 52.8%, stage 2), Group 4 (progressors, 8.9%, to stage 3/4), and Group 5 (stable high-risk, 15.8%, stage 3/4), from baseline distributions of stage 0 (1.6%), 1 (12.3%), 2 (71.0%), 3 (5.8%), and 4 (9.2%). Serum AGEs were quantified by UPLC-MS/MS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Higher AGEs levels showed significant associations with CKM severity, with each 1-SD increase corresponding to a 30% greater likelihood of advanced staging (95% CI:10%–54%). Quartile analysis revealed a dose–response relationship (Q2:1.66[1.15–2.41]; Q3:1.67[1.12–2.48]; Q4:1.92[1.31–2.81]). Longitudinally, the total AGEs score was significantly associated with CKM transition patterns from 2019 to 2022. The odds ratios (ORs) for Group 2, Group 3, Group 4, and Group 5 compared to Group 1 were 1.61 (1.06–2.45), 1.64 (1.11–2.41), 1.71 (1.07–2.73), and 2.03 (1.32–3.13), respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest that serum AGEs are linked to CKM severity and progression, potentially serving as biomarkers for CKM staging and targets for intervention.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70137","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144885052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplementing Inosine to Blood Collection Tubes Adds a Glycolytic Inhibitory Effect","authors":"Yukio Kume,&nbsp;Motohiro Ohkubo,&nbsp;Naru NaKatuka,&nbsp;Sayaka Aritake-Okada,&nbsp;Teruhiko Yoshida,&nbsp;Hideaki Isago,&nbsp;Makoto Kurano","doi":"10.1111/1753-0407.70144","DOIUrl":"https://doi.org/10.1111/1753-0407.70144","url":null,"abstract":"&lt;p&gt;At present, sodium fluoride (NaF)-supplemented tubes are used as usual blood collection tubes that can measure glucose and glycated hemoglobin (HbA1c) simultaneously. However, blood collection with NaF tubes show a decrease in glucose levels at room temperature within 4 h after blood collection [&lt;span&gt;1&lt;/span&gt;]. The American Diabetes Association (ADA) guidelines recommend immersion of blood samples collected with heparin-lithium (Hp-Li) in ice water within 30 min or the use of tubes containing NaF and citrate buffer (FC) [&lt;span&gt;2&lt;/span&gt;]. However, immediate immersion in ice water is difficult in clinical practice and citric acid is difficult to dissolve and is not suitable for HbA1c measurements because of hemolysis. Therefore, we aimed to develop blood collection tubes that are easier for clinical use than FC tubes and minimize blood glucose decline, compared with NaF tubes.&lt;/p&gt;&lt;p&gt;We collected 2 mL of whole blood each tube. Immediately after blood collection, each tube was agitated on a mix rotator at 3000 rpm (1470 g) for 5 min and then stored under storage conditions until immediately before measurement. The aliquoted blood collection tubes were stored at room temperature (25°C) or refrigerated (4°C). Then, the aliquoted whole blood was plasma-separated by centrifugation immediately and 2, 4, 24, and 48 h after collection. Glucose was measured immediately after separation, as well as HbA1c.&lt;/p&gt;&lt;p&gt;Changes in blood glucose levels in the NaF, FI, and FC tubes are shown in Figure 1A–D. Blood glucose changes were significantly attenuated to a greater degree in FI tubes than in NaF tubes at 4°C and 25°C conditions 4 and 24 h after sampling, whereas the blood glucose-preserving abilities of FI tubes were significantly inferior to those of FC tubes, except the case when stored at 4°C for 4 h. Regarding the criteria required from ADA (within 6.1% of the baseline blood glucose levels), the storage of FI blood collection tubes at 4°C did not reduce blood glucose levels by &gt; 6.1%, which is the criteria required from ADA, in any sample up to 48 h, whereas the storage of FI blood collection tubes at room temperature reduced blood glucose levels by &gt; 6.1% in 1 of 10 cases after 24 h (Figure S2), which were much superior to the NF tubes (Figures S1 and S2).&lt;/p&gt;&lt;p&gt;In addition, the enzymatic and immunoassay methods showed a significant difference with a &lt;i&gt;p&lt;/i&gt; value of 0.005 in FC blood tubes, whereas no significant difference was observed for the FI blood tubes (Figure 1E,E). Concordantly, no significant difference in hemolytic Hb levels was observed in the NaF and FI tubes, but not in FC tubes, compared with Hp-Li tubes (Figure S4).&lt;/p&gt;&lt;p&gt;Regarding the mechanism, although the detail mechanisms will be published somewhere else, the inhibitory effects on ATP and glucose uptake decline in erythrocytes were considered. We believe that inosine addition to the NaF blood collection tube would contribute to measuring the blood glucose levels exactly, witho","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144869592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Degree Family History of Diabetes Is Associated With the Presence of Depressive Symptoms Independent of Lifestyle Risk Factors and Cardiometabolic Risk Factors","authors":"Mengying Chen,&nbsp;Huimin Xia,&nbsp;Yaohui Yu,&nbsp;Yuhua Wang,&nbsp;Wei Chen,&nbsp;Enyu Lou,&nbsp;Zhezhe Tang,&nbsp;Lijuan Yang,&nbsp;Shengjie Ge,&nbsp;Bo Yang,&nbsp;Xuejiang Gu,&nbsp;Xiang Hu","doi":"10.1111/1753-0407.70139","DOIUrl":"https://doi.org/10.1111/1753-0407.70139","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Co-occurrence of depression and diabetes is a prototypical example of mental-physical comorbidity. This study aims to investigate the association between first-degree family history of diabetes (FHD) and the presence of depressive symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The present work was one part of the baseline survey from the REACTION study. First-degree FHD was defined as having one or more first-degree relatives with diabetes. The Patient Health Questionnaire-9 was administered to detect the presence of depressive symptoms with its score ≥ 5. Logistic regression analyses were performed to determine the association between first-degree FHD and the presence of depressive symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 4804 participants were enrolled in the present study. Individuals with first-degree FHD were more likely to suffer from depressive symptoms compared with those without first-degree FHD (7.2% versus 4.9%, <i>p</i> = 0.004). The odds ratio (OR) of depressive symptoms was increased by 49.8% with the presence of first-degree FHD after adjustment of gender, age, socioeconomic factors, lifestyle risk factors, and cardiometabolic risk factors (<i>p</i> = 0.007). There were no significant interactions of gender, age, each socioeconomic factor, lifestyle risk factor, and cardiometabolic risk factors on the association between first-degree FHD and the presence of depressive symptoms, respectively (all <i>p</i> &gt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>First-degree FHD was associated with depressive symptoms independent of socioeconomic factors, lifestyle risk factors, and cardiometabolic risk factors. Genetic background might mainly contribute to the familial aggregation of depressive symptoms in individuals with first-degree FHD, who should be paid early attention to their mental health.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144861889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients With Type 2 Diabetes: A National Prospective Cohort Study: A Commentary","authors":"Nimra Khan,&nbsp; Rida-e-Zehra,&nbsp;Nandni Dileep","doi":"10.1111/1753-0407.70146","DOIUrl":"https://doi.org/10.1111/1753-0407.70146","url":null,"abstract":"<p>This commentary discusses the study “Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients with Type 2 Diabetes: A National Prospective Cohort Study” by Xi et al. The study provides a perceptive investigation of how metabolic characteristics and genetic variables interact to affect body mass index (BMI) in people with T2D. It has some limitations, including reliance on self-reported sleep data and lack of in-depth sleep quality assessment. We highlight the importance of objective sleep data, detailed assessments of sleep quality, and advanced polygenic risk models in future research to better understand these relationships and inform precision diabetes care.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144853664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}